Government-Owned Inventions; Availability for Licensing, 35787 [2016-13112]
Download as PDF
<![CDATA[
mstockstill on DSK3G9T082PROD with NOTICES
Federal Register / Vol. 81, No. 107 / Friday, June 3, 2016 / Notices
Written Comments: For Tribes:
consultation@ihs.gov.
For Urbans: urbanconfer@ihs.gov.
FOR FURTHER INFORMATION CONTACT:
CAPT Chris Buchanan, Acting Director,
Great Plains Area, Indian Health
Service, 115 4th Ave. SE Suite 309
Aberdeen, South Dakota, (605) 226–
7584, Fax (605) 226–7541.
SUPPLEMENTARY INFORMATION: These
meetings are in follow-up to the April
5–7, 2016 IHS Tribal Leaders Briefing in
Sioux Falls, South Dakota. The IHS
would like to invite the Great Plains
Area Tribal Leaders to participate in
formal consultation and interested
urban Indian organizations to confer
with IHS leadership to discuss the state
of the Great Plains Area IHS.
The purpose of these sessions are to
receive feedback on the organization of
the IHS Great Plains Area Office in an
effort to continue to become more
patient-focused in order to better meet
the needs of the American Indians in
the Great Plains Area. Specific topics
will include geographic location of the
Great Plains Area Office, centralization
or further decentralization of area office
services, staffing, budget, local
involvement, transparency and
oversight, partnerships, accountability,
and monitoring.
Tribal leaders and designated
representatives as well as urban Indian
organizations that are interested in
submitting written testimony for the onsite or telephonic consultation and
urban confer sessions can provide
written comments to the following: For
Tribes—consultation@ihs.gov. For
Urbans—urbanconfer@ihs.gov.
The Tribal consultation and urban
confer sessions will be conducted with
elected or appointed leaders of Tribal
governments and their designated
representatives [42 U.S.C. 9835, Section
640(l)(4)(A)], and recognized
representatives from urban Indian
organizations, as defined by 25 U.S.C.
1603(29). Representatives from other
Tribal organizations and Native nonprofit organizations are welcome to
attend as observers. Those wishing to
participate in the discussions must have
a copy of a letter signed by an elected
or appointed official or their designee,
which authorizes them to serve as a
representative of the Tribe. This should
be submitted no later than three days in
advance of the Tribal consultation and
urban confer session to CAPT Chris
Buchanan at (605) 226–7541 (fax).
A detailed report of all written
comments and comments received
through the Tribal consultation and
urban confer sessions will be prepared
and made available within 90 days of
VerDate Sep<11>2014
21:20 Jun 02, 2016
Jkt 238001
the close of the comment period to all
Tribal governments and interested
urban Indian organizations within the
Great Plains Area.
Dated: May 27, 2016.
Mary Smith,
Principal Deputy Director, Indian Health
Service.
[FR Doc. 2016–13135 Filed 6–2–16; 8:45 am]
BILLING CODE 4165–16–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209
and 37 CFR part 404 to achieve
expeditious commercialization of
results of federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing and/or co-development.
ADDRESSES: Invention Development and
Marketing Unit, Technology Transfer
Center, National Cancer Institute, 9609
Medical Center Drive, Mail Stop 9702,
Rockville, MD 20850–9702.
FOR FURTHER INFORMATION CONTACT:
Information on licensing and codevelopment research collaborations,
and copies of the U.S. patent
applications listed below, may be
obtained by contacting: Attn. Invention
Development and Marketing Unit,
Technology Transfer Center, National
Cancer Institute, 9609 Medical Center
Drive, Mail Stop 9702, Rockville, MD
20850–9702, Tel. 240–276–5515 or
email ncitechtransfer@mail.nih.gov. A
signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Title of invention: Chimeric Antigen
Receptors to CD276 for treating Cancer.
Description of Technology: Chimeric
antigen receptors (CARs) are hybrid
proteins consisting of an antibody
binding fragment fused to protein
signaling domains that cause T-cells
which express the CAR to become
cytotoxic. Once activated, these
cytotoxic T-cells can selectively
SUMMARY:
PO 00000
Frm 00055
Fmt 4703
Sfmt 9990
35787
eliminate the cells which they recognize
via the antibody binding fragment of the
CAR. By engineering a T-cell to express
a CAR that is specific for a certain cell
surface protein, it is possible to
selectively target those cells for
destruction. This is a promising new
therapeutic approach known as
adoptive cell therapy.
CD276 (a.k.a., B7–H3) is a tumorassociated antigen that is expressed on
the cell surface of several cancers,
including neuroblastomas, prostate
cancer, ovarian cancer and some lung
cancers. This technology concerns the
development of CARs comprising an
antigen-binding fragment derived from
the MGA271 antibody. The resulting
CARs can be used in adoptive cell
therapy treatment for neuroblastoma
and other tumors which express CD276.
Potential Commercial Applications:
• Treatment of cancers associated
with expression of CD276.
• Specific cancers include
neuroblastoma, prostate cancer, ovarian
cancer, lung cancer and other solid
tumors.
Value Proposition:
• MGA271 is a well characterized
anti-CD276 antibody, making it a known
quantity regarding safety issues.
• High affinity of the MGA271
antibody for CD276 increases the
likelihood of successful targeting.
• Targeted therapy decreases nonspecific killing of healthy, essential
cells, resulting in fewer non-specific
side-effects and healthier patients.
Development Stage: Discovery (Lead
ID).
Inventor(s): Crystal Mackall.
Intellectual Property: HHS No. E–243–
2015/0–US–01 U.S. Provisional
Application 62/216,447 (E–243–2015/0–
US–01) filed 9/10/2015 titled ‘‘AntiCD276 Chimeric Antigen Receptors’’.
Publications: None applicable.
Collaboration Opportunity:
Researchers at the NCI seek licensing for
chimeric antigen receptors to CD276 for
treating cancer.
Contact Information: Requests for
copies of the patent application or
inquiries about licensing, research
collaborations, and co-development
opportunities should be sent to John D.
Hewes, Ph.D., email:
john.hewes@nih.gov.
Dated: May 31, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology
Transfer Center, National Cancer Institute.
[FR Doc. 2016–13112 Filed 6–2–16; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\03JNN1.SGM
03JNN1
]]>Agencies
[Federal Register Volume 81, Number 107 (Friday, June 3, 2016)]
[Notices]
[Page 35787]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-13112]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve
expeditious commercialization of results of federally-funded research
and development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing and/or co-development.
ADDRESSES: Invention Development and Marketing Unit, Technology
Transfer Center, National Cancer Institute, 9609 Medical Center Drive,
Mail Stop 9702, Rockville, MD 20850-9702.
FOR FURTHER INFORMATION CONTACT: Information on licensing and co-
development research collaborations, and copies of the U.S. patent
applications listed below, may be obtained by contacting: Attn.
Invention Development and Marketing Unit, Technology Transfer Center,
National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702,
Rockville, MD 20850-9702, Tel. 240-276-5515 or email
ncitechtransfer@mail.nih.gov. A signed Confidential Disclosure
Agreement may be required to receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Title of invention: Chimeric Antigen Receptors to CD276 for
treating Cancer.
Description of Technology: Chimeric antigen receptors (CARs) are
hybrid proteins consisting of an antibody binding fragment fused to
protein signaling domains that cause T-cells which express the CAR to
become cytotoxic. Once activated, these cytotoxic T-cells can
selectively eliminate the cells which they recognize via the antibody
binding fragment of the CAR. By engineering a T-cell to express a CAR
that is specific for a certain cell surface protein, it is possible to
selectively target those cells for destruction. This is a promising new
therapeutic approach known as adoptive cell therapy.
CD276 (a.k.a., B7-H3) is a tumor-associated antigen that is
expressed on the cell surface of several cancers, including
neuroblastomas, prostate cancer, ovarian cancer and some lung cancers.
This technology concerns the development of CARs comprising an antigen-
binding fragment derived from the MGA271 antibody. The resulting CARs
can be used in adoptive cell therapy treatment for neuroblastoma and
other tumors which express CD276.
Potential Commercial Applications:
Treatment of cancers associated with expression of CD276.
Specific cancers include neuroblastoma, prostate cancer,
ovarian cancer, lung cancer and other solid tumors.
Value Proposition:
MGA271 is a well characterized anti-CD276 antibody, making
it a known quantity regarding safety issues.
High affinity of the MGA271 antibody for CD276 increases
the likelihood of successful targeting.
Targeted therapy decreases non-specific killing of
healthy, essential cells, resulting in fewer non-specific side-effects
and healthier patients.
Development Stage: Discovery (Lead ID).
Inventor(s): Crystal Mackall.
Intellectual Property: HHS No. E-243-2015/0-US-01 U.S. Provisional
Application 62/216,447 (E-243-2015/0-US-01) filed 9/10/2015 titled
``Anti-CD276 Chimeric Antigen Receptors''.
Publications: None applicable.
Collaboration Opportunity: Researchers at the NCI seek licensing
for chimeric antigen receptors to CD276 for treating cancer.
Contact Information: Requests for copies of the patent application
or inquiries about licensing, research collaborations, and co-
development opportunities should be sent to John D. Hewes, Ph.D.,
email: john.hewes@nih.gov.
Dated: May 31, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology Transfer Center, National
Cancer Institute.
[FR Doc. 2016-13112 Filed 6-2-16; 8:45 am]
BILLING CODE 4140-01-P
